Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products

Wiley Interdisciplinary Reviews: Systems Biology and Medicine

Volumn 1, Issue 2, 2009, Pages 254-272

  Pozzi, Ambra ^a   Zent, Roy ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; ARACHIDONIC ACID; COLLAGEN; CYTOCHROME P450; ICOSANOID; LAMININ; LIPOXYGENASE; PERLECAN; PROSTAGLANDIN SYNTHASE; PROTEOHEPARAN SULFATE;

ANGIOGENESIS; ANIMAL; BASEMENT MEMBRANE; BIOLOGICAL MODEL; CYTOLOGY; ENDOTHELIUM CELL; HUMAN; NEOPLASM; PHYSIOLOGY; REVIEW; SYSTEMS BIOLOGY; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ARACHIDONIC ACID; BASEMENT MEMBRANE; COLLAGEN; CYTOCHROME P-450 ENZYME SYSTEM; EICOSANOIDS; ENDOTHELIAL CELLS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LAMININ; LIPOXYGENASES; MODELS, BIOLOGICAL; NEOPLASMS; NEOVASCULARIZATION, PHYSIOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SYSTEMS BIOLOGY;

EID: 79952116210     PISSN: 19395094     EISSN: 1939005X     Source Type: Journal    
DOI: 10.1002/wsbm.7     Document Type: Article

References (167)

1. Alghisi GC, Ruegg C. Vascular integrins in tumor angiogenesis: mediators and therapeutic targets. Endothelium 2006, 13:113-135.
2. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
3. Shojaei F, Zhong C, Wu X, Yu L, Ferrara N. Role of myeloid cells in tumor angiogenesis and growth. Trends Cell Biol 2008, 18:372-378.
4. Dirkx AE, Oude Egbrink MG, Wagstaff J, Griffioen AW. Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol 2006, 80:1183-1196.
5. Crivellato E, Nico B, Ribatti D. Mast cells and tumour angiogenesis: new insight from experimental carcinogenesis. Cancer Lett 2008, 269:1-6.
6. Noonan DM, De Lerma Barbaro A, Vannini N, Mortara L, Albini A. Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer Metastasis Rev 2008, 27:31-40.
7. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol 2007, 19:209-216.
8. Johansson M, Denardo DG, Coussens LM. Polarized immune responses differentially regulate cancer development. Immunol Rev 2008, 222:145-154.
9. Zhang B, Cao H, Rao GN. Fibroblast growth factor-2 is a downstream mediator of phosphatidylinositol 3-kinase-Akt signaling in 14,15-epoxyeicosatrienoic acid-induced angiogenesis. J Biol Chem 2006, 281:905-914.
10. Cheranov SY, KarpurapuM, Wang D, Zhang B, Venema RC, et al. An essential role for SRC-activated STAT-3 in 14,15-EET-induced VEGF expression and angiogenesis. Blood 2008, 111:5581-5591.
11. Finetti F, SolitoR, Morbidelli L, Giachetti A, ZicheM, et al. Prostaglandin E2 regulates angiogenesis via activation of fibroblast growth factor receptor-1. J Biol Chem 2008, 283:2139-2146.
12. Gupta RA, Tejada LV, Tong BJ, Das SK, Morrow JD, et al. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res 2003, 63:906-911.
13. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-716.
14. Nie D, Tang K, Diglio C, Honn KV. Eicosanoid regulation of angiogenesis: role of endothelial arachidonate 12-lipoxygenase. Blood 2000, 95:2304-2311.
15. Nie D, Krishnamoorthy S, Jin R, Tang K, Chen Y, et al. Mechanisms regulating tumor angiogenesis by 12-lipoxygenase in prostate cancer cells. J Biol Chem 2006, 281:18601-18609.
16. Ishibashi M, Bottone FG Jr, Taniura S, Kamitani H, Watanabe T, et al. The cyclooxygenase inhibitor indomethacin modulates gene expression and represses the extracellular matrix protein laminin gamma1 in human glioblastoma cells. Exp Cell Res 2005, 302:244-252.
17. Kang SW, Natarajan R, Shahed A, Nast CC, LaPage J, et al. Role of 12-lipoxygenase in the stimulation of p38 mitogen-activated protein kinase and collagen alpha5(IV) in experimental diabetic nephropathy and in glucose-stimulated podocytes. J Am Soc Nephrol 2003, 14:3178-3187.
18. Huang S, Wettlaufer SH, Hogaboam C, Aronoff DM, Peters-Golden M. Prostaglandin E(2) inhibits collagen expression and proliferation in patient-derived normal lung fibroblasts via E prostanoid 2 receptor and cAMP signaling. Am J Physiol Lung Cell Mol Physiol 2007, 292:L405-L413.
19. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, Falck JR, Fleming I, et al. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci 2005, 118:5489-5498.
20. Yen JH, Khayrullina T, Ganea D. PGE2-induced metalloproteinase-9 is essential for dendritic cell migration. Blood 2008, 111:260-270.
21. Pavlovic S, Du B, Sakamoto K, Khan KM, Natarajan C, et al. Targeting prostaglandin E2 receptors as an alternative strategy to block cyclooxygenase-2-dependent extracellular matrix-induced matrix metalloproteinase-9 expression by macrophages. J Biol Chem2006, 281:3321-3328.
22. Khan KM, Howe LR, Falcone DJ. Extracellular matrix-induced cyclooxygenase-2 regulates macrophage proteinase expression. J Biol Chem2004, 279:22039-22046.
23. Moshal KS, Zeldin DC, Sithu SD, Sen U, Tyagi N, et al. Cytochrome P450 (CYP) 2J2 gene transfection attenuates MMP-9 via inhibition of NFkappabeta in hyperhomocysteinemia. J Cell Physiol 2008, 215:771-781.
24. Boosani CS, Mannam AP, Cosgrove D, Silva R, Hodivala-Dilke KM, et al. Regulation of COX-2 mediated signaling by alpha3 type IV noncollagenous domain in tumor angiogenesis. Blood 2007, 110:1168-1177.
25. Khoshnoodi J, Pedchenko V, Hudson BG. Mammalian collagen IV. Microsc Res Tech 2008, 71:357-370.
26. Bix G, Iozzo RV. Novel interactions of perlecan: unraveling perlecan's role in angiogenesis. Microsc Res Tech 2008, 71:339-348.
27. Miner JH. Laminins and their roles in mammals. Microsc Res Tech 2008, 71:349-356.
28. Ho MS, Bose K, Mokkapati S, Nischt R, Smyth N. Nidogens-Extracellular matrix linker molecules. Microsc Res Tech 2008, 71:387-395.
29. LeBleu VS, Macdonald B, Kalluri R. Structure and function of basement membranes. Exp Biol Med (Maywood) 2007, 232:1121-1129.
30. Mongiat M, Sweeney SM, San Antonio JD, Fu J, Iozzo RV. Endorepellin, a novel inhibitor of angiogenesis derived from the C terminus of perlecan. J Biol Chem 2003, 278:4238-4249.
31. Bix G, Fu J, Gonzalez EM, Macro L, Barker A, et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J Cell Biol 2004, 166:97-109.
32. Woodall BP, Nystrom A, Iozzo RA, Eble JA, Niland S et al. Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity. J Biol Chem 2008, 283:2335-2343.
33. Bix G, Castello R, Burrows M, Zoeller JJ, Weech M, et al. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J Natl Cancer Inst 2006, 98:1634-1646.
34. Ponce ML, Nomizu M, Delgado MC, Kuratomi Y, Hoffman MP, et al. Identification of endothelial cell binding sites on the laminin gamma 1 chain. Circ Res 1999, 84:688-694.
35. Ponce ML, Nomizu M, Kleinman HK. An angiogenic laminin site and its antagonist bind through the alpha(v)beta3 and alpha5beta1 integrins. Faseb J 2001, 15:1389-1397.
36. Kuratomi Y, Nomizu M, Tanaka K, Ponce ML, Komiyama S, et al. Laminin gamma 1 chain peptide, C-16 (KAFDITYVRLKF), promotes migration, MMP-9 secretion, and pulmonary metastasis of B16-F10 mouse melanoma cells. Br J Cancer 2002, 86:1169-1173.
37. Malinda KM, Nomizu M, Chung M, Delgado M, Kuratomi Y, et al. Identification of laminin alpha1 and beta1 chain peptides active for endothelial cell adhesion, tube formation, and aortic sprouting. Faseb J 1999, 13:53-62.
38. DeHahn KC, Gonzales M, Gonzalez AM, Hopkinson SB, Chandel NS, et al. The alpha4 laminin subunit regulates endothelial cell survival. Exp Cell Res 2004, 294:281-289.
39. Sudhakar A, Nyberg P, Keshamouni VG, Mannam AP, Li J, et al. Human alpha1 type IV collagen NC1 domain exhibits distinct antiangiogenic activity mediated by alpha1beta1 integrin. J Clin Invest 2005, 115:2801-2810.
40. Petitclerc E, Boutaud A, Prestayko A, Xu J, Sado Y, et al. New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo. J Biol Chem 2000, 275:8051-8061.
41. He GA, Luo JX, Zhang TY, Hu ZS, Wang FY. The C-terminal domain of canstatin suppresses in vivo tumor growth associated with proliferation of endothelial cells. Biochem Biophys Res Commun 2004, 318:354-360.
42. He GA, Luo JX, Zhang TY, Wang FY, Li RF. Canstatin-N fragment inhibits in vitro endothelial cell proliferation and suppresses in vivo tumor growth. Biochem Biophys Res Commun 2003, 312:801-805.
43. Kamphaus GD, Colorado PC, Panka DJ, Hopfer H, Ramchandran R, et al. Canstatin, a novel matrixderived inhibitor of angiogenesis and tumor growth. J Biol Chem 2000, 275:1209-1215.
44. Magnon C, Galaup A, Mullan B, Rouffiac V, Bouquet C, et al. Canstatin acts on endothelial and tumor cells viamitochondrial damage initiated through interaction with alphavbeta3 and alphavbeta5 integrins. Cancer Res 2005, 65:4353-4361.
45. Miyoshi T, Hirohata S, Ogawa H, Doi M, Obika M, et al. Tumor-specific expression of the RGDalpha3(IV)NC1 domain suppresses endothelial tube formation and tumor growth in mice. Faseb J 2006, 20:1904-1906.
46. Maeshima Y, Colorado PC, Kalluri R. Two RGDindependent alpha vbeta 3 integrin binding sites on tumstatin regulate distinct anti-tumor properties. J Biol Chem 2000, 275:23745-23750.
47. Maeshima Y, Sudhakar A, Lively JC, Ueki K, Kharbanda S, et al. Tumstatin, an endothelial cellspecific inhibitor of protein synthesis. Science 2002, 295:140-143.
48. Borza CM, Pozzi A, Borza DB, Pedchenko V, Hellmark T, et al. Integrin alpha3beta1, a novel receptor for alpha3(IV) noncollagenous domain and a transdominant Inhibitor for integrin alphavbeta3. J Biol Chem 2006, 281:20932-20939.
49. Pedchenko V, Zent R, Hudson BG. Alpha(v)beta3 and alpha(v)beta5 integrins bind both the proximal RGD site and non-RGD motifs within noncollagenous (NC1) domain of the alpha3 chain of type IV collagen: implication for the mechanism of endothelia cell adhesion. J Biol Chem2004, 279:2772-2780.
50. Shahan TA, Ziaie Z, Pasco S, Fawzi A, Bellon G, et al. Identification of CD47/integrin-associated protein and alpha(v)beta3 as two receptors for the alpha3(IV) chain of type IV collagen on tumor cells. Cancer Res 1999, 59:4584-4590.
51. Pasco S, Monboisse JC, Kieffer N. The alpha 3(IV)185-206 peptide from noncollagenous domain 1 of type IV collagen interacts with a novel binding site on the beta 3 subunit of integrin alpha Vbeta 3 and stimulates focal adhesion kinase and phosphatidylinositol 3-kinase phosphorylation. J Biol Chem 2000, 275:32999-33007.
52. Kawaguchi T, Yamashita Y, Kanamori M, Endersby R, Bankiewicz KS, et al. The PTEN/Akt pathway dictates the direct alphaVbeta3-dependent growthinhibitory action of an active fragment of tumstatin in glioma cells in vitro and in vivo. Cancer Res 2006, 66:11331-11340.
53. Mundel TM, Yliniemi AM, Maeshima Y, Sugimoto H, Kieran M, et al. Type IV collagen alpha6 chainderived noncollagenous domain 1 (alpha6(IV)NC1) inhibits angiogenesis and tumor growth. Int J Cancer 2008, 122:1738-1744.
54. Heljasvaara R, Nyberg P, Luostarinen J, Parikka M, Heikkila P, et al. Generation of biologically active endostatin fragments from human collagen XVIII by distinct matrix metalloproteases. Exp Cell Res 2005, 307:292-304.
55. Kreuger J, Matsumoto T, VanwildemeerschM, Sasaki T, Timpl R, et al. Role of heparan sulfate domain organization in endostatin inhibition of endothelial cell function. Embo J 2002, 21:6303-6311.
56. Eriksson K, Magnusson P, Dixelius J, Claesson-Welsh L, Cross MJ. Angiostatin and endostatin inhibit endothelial cell migration in response to FGF and VEGF without interfering with specific intracellular signal transduction pathways. FEBS Lett 2003, 536:19-24.
57. Lee SJ, Jang JW, Kim YM, Lee HI, Jeon JY, et al. Endostatin binds to the catalytic domain of matrix metalloproteinase-2. FEBS Lett 2002, 519:147-152.
58. Kim YM, Jang JW, Lee OH, Yeon J, Choi EY, et al. Endostatin inhibits endothelial and tumor cellular invasion by blocking the activation and catalytic activity of matrix metalloproteinase. Cancer Res 2000, 60:5410-5413.
59. Karumanchi SA, Jha V, Ramchandran R, KarihalooA, Tsiokas L, et al. Cell surface glypicans are low-affinity endostatin receptors. Mol Cell 2001, 7:811-822.
60. Wickstrom SA, Alitalo K, Keski-Oja J. An endostatinderived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells. J Biol Chem 2004, 279:20178-20185.
61. Rehn M, Veikkola T, Kukk-Valdre E, Nakamura H, Ilmonen M, et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc Natl Acad Sci U S A 2001, 98:1024-1029.
62. Sudhakar A, Sugimoto H, Yang C, Lively J, Zeisberg M, et al. Human tumstatin and human endostatin exhibit distinct antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc Natl Acad Sci U S A 2003, 100:4766-4771.
63. Wickstrom SA, Alitalo K, Keski-Oja J. Endostatin associates with integrin alpha5beta1 and caveolin-1, and activates Src via a tyrosyl phosphatase-dependent pathway in human endothelial cells. Cancer Res 2002, 62:5580-5589.
64. Iozzo RV. Heparan sulfate proteoglycans: intricate molecules with intriguing functions. J Clin Invest 2001, 108:165-167.
65. Aviezer D, Hecht D, Safran M, Eisinger M, David G, et al. Perlecan, basal lamina proteoglycan, promotes basic fibroblast growth factor-receptor binding, mitogenesis, and angiogenesis. Cell 1994, 79:1005-1013.
66. Iozzo RV. Perlecan: a gem of a proteoglycan. Matrix Biol 1994, 14:203-208.
67. Sharma B, Handler M, Eichstetter I, Whitelock JM, Nugent MA, et al. Antisense targeting of perlecan blocks tumor growth and angiogenesis in vivo. J Clin Invest 1998, 102:1599-1608.
68. Colognato H, Yurchenco PD. Form and function: the laminin family of heterotrimers. Dev Dyn 2000, 218:213-234.
69. Sasaki T, Giltay R, Talts U, Timpl R, Talts JF. Expression and distribution of laminin alpha1 and alpha2 chains in embryonic and adult mouse tissues:an immunochemical approach. Exp Cell Res 2002, 275:185-199.
70. Dixelius J, Jakobsson L, Genersch E, Bohman S, Ekblom P, et al. Laminin-1 promotes angiogenesis in synergy with fibroblast growth factor by distinct regulation of the gene and protein expression profile in endothelial cells. J Biol Chem 2004, 279:23766-23772.
71. Hudson BG, Tryggvason K, Sundaramoorthy M, Neilson EG. Alport's syndrome, Goodpasture's syndrome, and type IV collagen. N Engl J Med 2003, 348:2543-2556.
72. Maeshima Y, Yerramalla UL, Dhanabal M, Holthaus KA, Barbashov S, et al. Extracellular matrix-derived peptide binds to alpha(v)beta(3) integrin and inhibits angiogenesis. J Biol Chem2001, 276:31959-31968.
73. Maeshima Y, Manfredi M, Reimer C, Holthaus KA, Hopfer H, et al. Identification of the anti-angiogenic site within vascular basement membrane-derived tumstatin. J Biol Chem 2001, 276:15240-15248.
74. Sudhakar A, Boosani CS. Inhibition of tumor angiogenesis by Tumstatin: insights into signaling mechanisms and implications in cancer regression. Pharm Res 2008, 12:2731.
75. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
76. Ricard-Blum S, Feraud O, Lortat-Jacob H, Rencurosi A, Fukai N, et al. Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations. J Biol Chem 2004, 279:2927-2936.
77. Italiano JE Jr, Richardson JL, Patel-Hett S, Battinelli E, Zaslavsky A, et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood 2008, 111:1227-1233.
78. Ma L, del Soldato P, Wallace JL. Divergent effects of new cyclooxygenase inhibitors on gastric ulcer healing: Shifting the angiogenic balance. Proc Natl Acad Sci U S A 2002, 99:13243-13247.
79. Hohenester E, Engel J. Domain structure and organisation in extracellular matrix proteins. Matrix Biol 2002, 21:115-128.
80. Sasaki T, Larsson H, Tisi D, Claesson-Welsh L, Hohenester E, et al. Endostatins derived from collagens XV and XVIII differ in structural and binding properties, tissue distribution and anti-angiogenic activity. J Mol Biol 2000, 301:1179-1190.
81. Ramchandran R, Dhanabal M, Volk R, Waterman MJ, Segal M, et al. Antiangiogenic activity of restin, NC10 domain of human collagen XV: comparison to endostatin. Biochem Biophys Res Commun 1999, 255:735-739.
82. Felbor U, Dreier L, Bryant RA, Ploegh HL, Olsen BR, et al. Secreted cathepsin L generates endostatin from collagen XVIII. Embo J 2000, 19:1187-1194.
83. Ferreras M, Felbor U, Lenhard T, Olsen BR, Delaisse J. Generation and degradation of human endostatin proteins by various proteinases. FEBS Lett 2000, 486:247-251.
84. Cailhier JF, Sirois I, Laplante P, Lepage S, Raymond MA, et al. Caspase-3 activation triggers extra-cellular cathepsin L release and endorepellin proteolysis. J Biol Chem 2008, 283:2720.
85. Wang B, Sun J, Kitamoto S, Yang M, Grubb A, et al. Cathepsin S controls angiogenesis and tumor growth via matrix-derived angiogenic factors. J Biol Chem 2006, 281:6020-6029.
86. Lin HC, Chang JH, Jain S, Gabison EE, Kure T, et al. Matrilysin cleavage of corneal collagen type XVIII NC1 domain and generation of a 28-kDa fragment. Invest Ophthalmol Vis Sci 2001, 42:2517-2524.
87. Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 2003, 3:589-601.
88. Wen W, Moses MA, Wiederschain D, Arbiser JL, Folkman J. The generation of endostatin is mediated by elastase. Cancer Res 1999, 59:6052-6056.
89. Gonzalez EM, Reed CC, Bix G, Fu J, Zhang Y, et al. BMP-1/Tolloid-like metalloproteases process endorepellin, the angiostatic C-terminal fragment of perlecan. J Biol Chem 2005, 280:7080-7087.
90. Michaelis UR, Fisslthaler B, Medhora M, Harder D, Fleming I, et al. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-talk with the epidermal growth factor receptor (EGFR). Faseb J 2003, 17:770-772.
91. Eibl G, Bruemmer D, Okada Y, Duffy JP, Law RE, et al. PGE(2) is generated by specific COX-2 activity and increases VEGF production in COX-2-expressing human pancreatic cancer cells. Biochem Biophys Res Commun 2003, 306:887-897.
92. Guo AM, Arbab AS, Falck JR, Chen P, Edwards PA, et al. Activation of vascular endothelial growth factor through reactive oxygen species mediates 20-hydroxyeicosatetraenoic acid-induced endothelial cell proliferation. J Pharmacol Exp Ther 2007, 321:18-27.
93. Pozzi A, Macias-Perez I, Abair T, Wei S, Su Y, et al. Characterization of 5,6- and 8,9-epoxyeicosatrienoic acids (5,6- and 8,9-EET) as potent in vivo angiogenic lipids. J Biol Chem 2005, 280:27138-27146.
94. Gately S, Li WW. Multiple roles of COX-2 in tumor angiogenesis: a target for antiangiogenic therapy. Semin Oncol 2004, 31:2-11.
95. Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000, 19:19-27.
96. Sugimoto Y, Narumiya S. Prostaglandin E receptors. J Biol Chem 2007, 282:11613-11617.
97. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors: subtypes and signaling. Annu Rev Pharmacol Toxicol 2001, 41:661-690.
98. Regan JW. EP2 and EP4 prostanoid receptor signaling. Life Sci 2003, 74:143-153.
99. FujinoH, XuW, Regan JW. Prostaglandin E2 induced functional expression of early growth response factor-1 by EP4, but not EP2, prostanoid receptors via the phosphatidylinositol 3-kinase and extracellular signal-regulated kinases. J Biol Chem 2003, 278:12151-12156.
100. Pozzi A, Yan X, Macias-Perez I, Wei S, Hata AN, et al. Colon carcinoma cell growth is associated with prostaglandin E2/EP4 receptor-evoked ERK activation. J Biol Chem2004, 279:29797-29804.
101. Sung YM, He G, Fischer SM. Lack of expression of the EP2 but not EP3 receptor for prostaglandin E2 results in suppression of skin tumor development. Cancer Res 2005, 65:9304-9311.
102. Kamiyama M, Pozzi A, Yang L, Debusk LM, Breyer RM, et al. EP2, a receptor for PGE(2), regulates tumor angiogenesis through direct effects on endothelial cellmotility and survival. Oncogene 2006, 53:7019-7028.
103. AmanoH, Hayashi I, Endo H, Kitasato H, Yamashina S, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J ExpMed 2003, 197:221-232.
104. Rao R, Redha R, Macias-Perez I, Su Y, Hao C, et al. Prostaglandin E2-EP4 receptor promotes endothelial cell migration via ERK activation and angiogenesis in vivo. J Biol Chem2007, 282:16959-16968.
105. AxelssonH, Lonnroth C, WangW, Svanberg E, Lundholm K. Cyclooxygenase inhibition in early onset of tumor growth and related angiogenesis evaluated in EP1 and EP3 knockout tumor-bearing mice. Angiogenesis 2005, 8:339-348.
106. Segi E, Sugimoto Y, Yamasaki A, Aze Y, Oida H, et al. Patent ductus arteriosus and neonatal death in prostaglandin receptor EP4-deficient mice. Biochem Biophys Res Commun 1998, 246:7-12.
107. Schneider A, Guan Y, Zhang Y, Magnuson MA, Pettepher C, et al. Generation of a conditional allele of the mouse prostaglandin EP4 receptor. Genesis 2004, 40:7-14.
108. Chen KH, Hsu WM, Chiang CC, Li YS. Transforming growth factor-beta2 inhibition of corneal endothelial proliferation mediated by prostaglandin. Curr Eye Res 2003, 26:363-370.
109. Pearce HR, Kalia N, Bardhan KD, Brown NJ. Effects of aspirin and indomethacin on endothelial cell proliferation in vitro. J Gastroenterol Hepatol 2003, 18:1180-1187.
110. Namkoong S, Lee SJ, Kim CK, Kim YM, Chung HT, et al. Prostaglandin E2 stimulates angiogenesis by activating the nitric oxide/cGMP pathway in human umbilical vein endothelial cells. Exp Mol Med 2005, 37:588-600.
111. Alfranca A, Lopez-Oliva JM, Genis L, Lopez-Maderuelo D, Mirones I, et al. PGE2 induces angiogenesis via MT1-MMP-mediated activation of the TGFbeta/Alk5 signaling pathway. Blood 2008, 112:1120-1128.
112. Lee EJ, Choi EM, Kim SR, Park JH, Kim H, et al. Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells. Exp Mol Med 2007, 39:469-476.
113. Pidgeon GP, Lysaght J, Krishnamoorthy S, Reynolds JV, O'Byrne K, et al. Lipoxygenase metabolism: roles in tumor progression and survival. Cancer Metastasis Rev 2007, 26:503-524.
114. Kim JA, Gu JL, Natarajan R, Berliner JA, Nadler JL. A leukocyte type of 12-lipoxygenase is expressed in human vascular and mononuclear cells. Evidence for upregulation by angiotensin II. Arterioscler Thromb Vasc Biol 1995, 15:942-948.
115. Tang DG, Renaud C, Stojakovic S, Diglio CA, Porter A, et al. 12(S)-HETE is a mitogenic factor for microvascular endothelial cells: its potential role in angiogenesis. Biochem Biophys Res Commun 1995, 211:462-468.
116. Tang DG, Timar J, Grossi IM, Renaud C, Kimler VA, et al. The lipoxygenase metabolite, 12(S)-HETE, induces a protein kinase C-dependent cytoskeletal rearrangement and retraction of microvascular endothelial cells. Exp Cell Res 1993, 207:361-375.
117. Tang DG, Chen YQ, Diglio CA, Honn KV. Protein kinase C-dependent effects of 12(S)-HETE on endothelial cell vitronectin receptor and fibronectin receptor. J Cell Biol 1993, 121:689-704.
118. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994, 264:569-571.
119. Zhang B, Cao H, Rao GN. 15(S)-hydroxyeicosatetraenoic acid induces angiogenesis via activation of PI3K-Akt-mTOR-S6K1 signaling. Cancer Res 2005, 65:7283-7291.
120. Bajpai AK, Blaskova E, Pakala SB, Zhao T, Glasgow WC, et al. 15(S)-HETE production in human retinal microvascular endothelial cells by hypoxia: Novel role for MEK1 in 15(S)-HETE induced angiogenesis. Invest Ophthalmol Vis Sci 2007, 48:4930-4938.
121. Srivastava K, Kundumani-Sridharan V, Zhang B, Bajpai AK, Rao GN. 15(S)-hydroxyeicosatetraenoic acid-induced angiogenesis requires STAT3-dependent expression of VEGF. Cancer Res 2007,67:4328-4336.
122. Harats D, Ben-Shushan D, Cohen H, Gonen A, Barshack I, et al. Inhibition of carcinogenesis in transgenic mouse models over-expressing 15-lipoxygenase in the vascular wall under the control of murine preproendothelin-1 promoter. Cancer Lett 2005, 229:127-134.
123. Viita H, Markkanen J, Eriksson E, NurminenM, Kinnunen K, et al. 15-lipoxygenase-1 prevents vascular endothelial growth factor A- and placental growth factor-induced angiogenic effects in rabbit skeletal muscles via reduction in growth factor mRNA levels, NO bioactivity, and downregulation of VEGF receptor 2 expression. Circ Res 2008, 102:177-184.
124. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006, 6:947-960.
125. Guengerich FP, Wu ZL, Bartleson CJ. Function of human cytochrome P450s: characterization of the orphans. Biochem Biophys Res Commun 2005, 338:465-469.
126. Capdevila JH, Falck JR. Biochemical and molecular properties of the cytochrome P450 arachidonic acid monooxygenases. Prostaglandins Other Lipid Mediat 2002, 68-69:325-344.
127. Spector AA, Fang X, Snyder GD, Weintraub NL. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog Lipid Res 2004, 43:55-90.
128. Michaelis UR, Fleming I. From endothelium-derived hyperpolarizing factor (EDHF) to angiogenesis: epoxyeicosatrienoic acids (EETs) and cell signaling. Pharmacol Ther 2006, 111:584-595.
129. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat 2007, 82:60-67.
130. Fleming I. Vascular cytochrome p450 enzymes: physiology and pathophysiology. Trends Cardiovasc Med 2008, 18:20-25.
131. Munzenmaier DH, Harder DR. Cerebral microvascular endothelial cell tube formation: role of astrocytic epoxyeicosatrienoic acid release. Am J Physiol Heart Circ Physiol 2000, 278(:):H1163-H1167.
132. Hoebel BG, Steyrer E, Graier WF. Origin and function of epoxyeicosatrienoic acids in vascular endothelial cells: more than just endothelium-derived hyperpolarizing factor? Clin Exp Pharmacol Physiol 1998, 25:826-830.
133. Michaelis UR, Falck JR, Schmidt R, Busse R, Fleming I. Cytochrome P4502C9-derived epoxyeicosatrienoic acids induce the expression of cyclooxygenase-2 in endothelial cells. Arterioscler Thromb Vasc Biol 2005, 25:321-326.
134. MedhoraM, Daniels J, Mundey K, Fisslthaler B, Busse R, et al. Epoxygenase-driven angiogenesis in human lung microvascular endothelial cells. Am J Physiol Heart Circ Physiol 2003, 284(:):H215-H224.
135. Chen JK, Capdevila J, Harris RC. Heparin-binding EGF-like growth factor mediates the biological effects of P450 arachidonate epoxygenase metabolites in epithelial cells. Proc Natl Acad Sci U S A 2002, 99:6029-6034.
136. Fleming I, Michaelis UR, Bredenkotter D, Fisslthaler B, Dehghani F, et al. Endothelium-derived hyperpolarizing factor synthase (Cytochrome P450 2C9) is a functionally significant source of reactive oxygen species in coronary arteries. Circ Res 2001, 88:44-51.
137. Chen P, Guo M, Wygle D, Edwards PA, Falck JR, et al. Inhibitors of cytochrome P450 4A suppress angiogenic responses. Am J Pathol 2005, 166:615-624.
138. Xu F, Ma Q, Sha H. Optimizing drug delivery for enhancing therapeutic efficacy of recombinant human endostatin in cancer treatment. Crit Rev Ther Drug Carrier Syst 2007, 24:445-492.
139. Macpherson GR, Ng SS, Forbes SL, Melillo G, Karpova T, et al. Anti-angiogenic activity of human endostatin is HIF-1-independent in vitro and sensitive to timing of treatment in a human saphenous vein assay. Mol Cancer Ther 2003, 2:845-854.
140. Morbidelli L, Donnini S, Chillemi F, Giachetti A, Ziche M. Angiosuppressive and angiostimulatory effects exerted by synthetic partial sequences of endostatin. Clin Cancer Res 2003, 9:5358-5369.
141. Fernando NT, Koch M, Rothrock C, Gollogly LK, D'Amore PA, et al. Tumor escape from endogenous, extracellular matrix-associated angiogenesis inhibitors by up-regulation of multiple proangiogenic factors. Clin Cancer Res 2008, 14:1529-1539.
142. Fawzi A, Robinet A, Monboisse JC, Ziaie Z, Kefalides NA, et al. A peptide of the alpha 3(IV) chain of type IV collagen modulates stimulated neutrophil function via activation of cAMP-dependent protein kinase and Ser/Thr protein phosphatase. Cell Signal 2000, 12:327-335.
143. Ziaie Z, Fawzi A, Bellon G, Monboisse JC, Kefalides NA. A peptide of the alpha3 chain of type IV collagen protects basement membrane against damage by PMN. Biochem Biophys Res Commun 1999, 261:247-250.
144. Gao X, Porter AT, Honn KV. Involvement of the multiple tumor suppressor genes and 12-lipoxygenase in human prostate cancer. Therapeutic implications. Adv Exp Med Biol 1997, 407:41-53.
145. Jiang WG, Douglas-Jones A, Mansel RE. Levels of expression of lipoxygenases and cyclooxygenase-2 in human breast cancer. Prostaglandins Leukot Essent Fatty Acids 2003, 69:275-281.
146. Gao X, Grignon DJ, Chbihi T, Zacharek A, Chen YQ, et al. Elevated 12-lipoxygenase mRNA expression correlates with advanced stage and poor differentiation of human prostate cancer. Urology 1995, 46:227-237.
147. Nie D, Honn KV. Cyclooxygenase, lipoxygenase and tumor angiogenesis. Cell Mol Life Sci 2002, 59:799-807.
148. Tong WG, Ding XZ, Witt RC, Adrian TE. Lipoxygenase inhibitors attenuate growth of human pancreatic cancer xenografts and induce apoptosis through the mitochondrial pathway. Mol Cancer Ther 2002, 1:929-935.
149. Witton CJ, Hawe SJ, Cooke TG, Bartlett JM. Cyclooxygenase 2 (COX2) expression is associated with poor outcome in ER-negative, but not ER-positive, breast cancer. Histopathology 2004, 45:47-54.
150. Buchanan FG, Holla V, Katkuri S, Matta P, DuBois RN. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res 2007, 67:9380-9388.
151. Wang L, Chen W, Xie X, He Y, Bai X. Celecoxib inhibits tumor growth and angiogenesis in an orthotopic implantation tumor model of human colon cancer. Exp Oncol 2008, 30:42-51.
152. Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989, 157:175-179.
153. Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991, 325:1593-1596.
154. Gupta RA, Dubois RN. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001, 1:11-21.
155. Cha YI, DuBois RN. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med 2007, 58:239-252.
156. FDA warning on NSAID use. FDA Consum 2005, 39:5.
157. Mukherjee D. Nonsteroidal anti-inflammatory drugs and the heart: what is the danger? Congest Heart Fail 2008, 14:75-82.
158. Reddy RN, Mutyala R, Aparoy P, Reddanna P, Reddy MR. Computer aided drug design approaches to develop cyclooxygenase based novel anti-inflammatory and anti-cancer drugs. Curr Pharm Des 2007, 13:3505-3517.
159. Pozzi A, Ibanez MR, Gatica AE, Yang S, Wei S, et al. Peroxisomal proliferator-activated receptoralpha-dependent inhibition of endothelial cell proliferation and tumorigenesis. J Biol Chem 2007, 282:17685-17695.
160. Panigrahy D, Kaipainen A, Huang S, Butterfield CE, Barnes CM, et al. PPARalpha agonist fenofibrate suppresses tumor growth through direct and indirect angiogenesis inhibition. Proc Natl Acad Sci U S A 2008, 105:985-990.
161. Goetze S, Eilers F, Bungenstock A, Kintscher U, Stawowy P, et al. PPAR activators inhibit endothelial cell migration by targeting Akt. Biochem Biophys Res Commun 2002, 293:1431-1437.
162. Varet J, Vincent L, Mirshahi P, Pille JV, Legrand E, et al. Fenofibrate inhibits angiogenesis in vitro and in vivo. Cell Mol Life Sci 2003, 60:810-819.
163. Kaipainen A, Kieran MW, Huang S, Butterfield C, Bielenberg D, et al. PPARalpha deficiency in inflammatory cells suppresses tumor growth. PLoS ONE 2007, 2:e260.
164. Pozzi A, Capdevila JH. PPARα ligands as antitumorigenic and antiangiogenic agents. PPAR Res 2008, 2008:Article ID 906542.
165. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999, 341:410-418.
166. FrickMH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987, 317:1237-1245.
167. Blann AD, Belgore FM, Constans J, Conri C, Lip GY. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am J Cardiol 2001, 87:1160-1163.